Alpha-kinase 1 agonists derived from microbial metabolite inflame antitumour immunity
Shilei Qiao, Zhengkui Zhang, Fangfang Zhou · 2026
Read Alpha-kinase 1 agonists derived from microbial metabolite inflame antitumour immunity by Shilei Qiao, Zhengkui Zhang, Fangfang Zhou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13179400.txt.
Description
Shilei Qiao and co-authors comment on a new cancer immunotherapy lead in a 2026 article about alpha-kinase 1. A recent study found that compounds derived from a microbial metabolite can switch on this bacterial-sensing enzyme and provoke strong antitumor immunity, outperforming better-known immune triggers in early comparisons.
The commentary explains why the target is attractive. Checkpoint drugs alone leave many patients unresponsive, while older innate immune agonists bring toxicity and uneven receptor coverage. Alpha-kinase 1 is expressed broadly across immune and other cells and directly boosts antigen presentation. That breadth, the authors argue, could help remodel cold, resistant tumors.
Catalog record
| CREATOR | Shilei Qiao, Zhengkui Zhang, Fangfang Zhou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 13 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |